Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres

For osteosarcoma that progresses following first-line chemotherapy, prognosis remains poor although anti-angiogenesis tyrosine kinase inhibitors (TKIs) have been verified to prolong progression-free survival. Apatinib has led to positive responses in the treatment of refractory osteosarcoma. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Lu, Xu, Jie, Sun, Xin, Li, Xiaowei, Liu, Kuisheng, Liang, Xin, Zhou, Zuli, Zhuang, Hongqing, Sun, Kunkun, Wu, Yiming, Gu, Jin, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170178/
https://www.ncbi.nlm.nih.gov/pubmed/34093773
http://dx.doi.org/10.3892/ol.2021.12813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170178/
https://www.ncbi.nlm.nih.gov/pubmed/34093773
http://dx.doi.org/10.3892/ol.2021.12813

Ejemplares similares